Nearly two out of every three Americans living with Alzheimer’s disease are women, according to the Alzheimer’s Association, yet for decades the scientific understanding of how the disease attacks the brain has treated sex as a footnote. A convergence of peer-reviewed research, much of it published in the last two years, is now dismantling that assumption. Studies using advanced brain imaging and blood-based biomarkers show that Alzheimer’s follows measurably different biological paths in men and women, with women facing faster metabolic decline and heavier accumulations of the toxic tau protein that drives neuronal death. The implications reach beyond the lab: if the disease behaves differently in the majority of patients, then treatments tested and dosed without accounting for sex may be missing the mark.
Divergent metabolic collapse
Among the most striking findings is a 2023 study in Experimental and Molecular Medicine that analyzed glucose metabolism dysfunction using FDG-PET brain scans, plasma biomarkers, and gene-expression data drawn from several hundred participants across independent clinical cohorts, though the authors did not release a single combined sample count. FDG-PET measures how efficiently neurons consume glucose, their primary fuel. When that process breaks down, brain cells starve and die. The researchers found that this metabolic collapse does not follow the same trajectory in both sexes. In women, the pattern of decline was distinct and, in certain brain regions, more pronounced, offering an independent biological signal beyond the tau tangles and brain shrinkage that had dominated earlier sex-difference research.
“The sex-specific metabolic signatures we identified suggest that women’s brains may be losing energy supply through pathways that are not captured by conventional staging,” the study’s authors wrote, underscoring the need for imaging protocols that account for biological sex.
That finding gains additional weight from analyses drawn from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a federally funded longitudinal dataset hosted at the University of Southern California. A study published in NeuroImage: Clinical found that female carriers of the APOE e4 gene showed higher regional tau PET signals and smaller gray matter volumes in specific brain areas compared with men carrying the same variant. APOE e4 is the single strongest known genetic risk factor for late-onset Alzheimer’s, and its danger scales with dosage: people who inherit one copy face elevated risk, while those who inherit two copies face a substantially higher likelihood of developing the disease. Critically, the NeuroImage: Clinical analysis showed that even among single-copy carriers, the gene’s impact is not uniform across sexes. In women who carry it, elevated tau and accelerated tissue loss appear to compound each other more severely.
A third variable: alpha-synuclein
A separate line of evidence examined whether sex modifies the relationship between alpha-synuclein co-pathology and longitudinal tau accumulation using ADNI tau-PET imaging. The analysis, led by Ece Kocagoncu and colleagues and published in JAMA Network Open in 2024, reported interaction effects suggesting that the presence of alpha-synuclein pathology accelerates tau buildup on different timelines depending on the patient’s sex. Alpha-synuclein is the misfolded protein most closely associated with Parkinson’s disease, but it also appears in a significant subset of Alzheimer’s patients. The finding adds yet another axis along which men’s and women’s brains diverge during disease progression.
Taken together, these three bodies of work, spanning metabolism, tau-gene interactions, and protein co-pathology, build a case that sex is not a secondary variable in Alzheimer’s biology. It is a primary one.
What the science has not yet settled
The convergence is compelling, but important gaps remain. The ADNI cohorts that underpin the tau and metabolism findings are predominantly white and recruited from academic research centers. Whether the same sex-specific patterns hold across different racial and ethnic groups, or in community clinic populations with less access to specialized care, is an open question. A large memory-unit cohort study published in Alzheimer’s Research and Therapy offered broader clinical data with sex-stratified breakdowns of diagnosis and biomarker features, but even that dataset reflects a single institutional setting.
The biological mechanisms behind these differences are also still being mapped. A 2024 review in Molecular Psychiatry cataloged several hypotheses, including the roles of sex hormones, sex chromosomes, neuroinflammation, and autophagy pathways, the cellular housekeeping systems that clear damaged proteins. Post-menopausal estrogen loss has long been proposed as a factor that could amplify neurodegeneration in women, but no clinical trial has demonstrated that hormone-based interventions slow Alzheimer’s progression in at-risk female patients. The review provides a useful explanatory framework, yet the field still lacks direct experimental confirmation of which mechanism, or combination of mechanisms, is responsible.
Another unresolved question involves APOE e4 itself. The NeuroImage: Clinical analysis showed that sex differences in tau deposition and gray matter volume were most pronounced among carriers of that variant. Whether similar gene-by-sex interactions exist for other Alzheimer’s risk genes has not been established. Researchers also have not determined whether the metabolic differences captured by FDG-PET translate directly into faster cognitive decline in women, or whether compensatory brain mechanisms offset some of the metabolic damage in earlier disease stages. Answering that will require longitudinal cognitive testing linked to repeated imaging over years.
Study design introduces its own caveats. Many current datasets enroll participants who are relatively well educated, medically stable, and motivated to join research. Those characteristics can shape both baseline brain health and access to care, potentially muting or exaggerating sex differences compared with what clinicians might observe in under-resourced or rural populations. Small sample sizes in some subgroups, such as men with both APOE e4 and alpha-synuclein co-pathology, mean that estimates of effect size carry wide statistical margins of error.
Why the treatment pipeline may need recalibrating
These findings arrive at a moment when the Alzheimer’s treatment landscape is shifting rapidly. The anti-amyloid antibodies lecanemab and donanemab have reached patients in the United States, but their pivotal trials were not primarily designed to detect sex-specific differences in efficacy or side effects. If women’s brains accumulate tau faster and lose metabolic function along a different curve, the window in which an amyloid-clearing drug can make a meaningful difference may not be the same for both sexes. As of spring 2026, no large-scale trial has published results stratified by sex in a way that answers that question definitively, though several ongoing studies have committed to doing so.
For patients and families, the practical significance is straightforward: Alzheimer’s is not a single-track disease. Women who carry the APOE e4 variant face a measurably different biological burden than men with the same genetic profile, and the metabolic trajectory of the disease in women’s brains follows a pattern that standard, sex-neutral clinical assessments may not fully capture.
Steps patients and families can take before their next appointment
Anyone with a family history of Alzheimer’s, particularly women, should discuss genetic risk factors and sex-specific screening options with a neurologist or genetic counselor. Those conversations can include whether to pursue APOE genotyping, how to interpret biomarker tests such as amyloid or tau PET scans, and what lifestyle or medical interventions might be appropriate given an individual’s risk profile.
No therapy has yet been proven to eliminate the sex gap in Alzheimer’s burden. But awareness of these differences can guide more personalized monitoring, shape eligibility and stratification in clinical trials, and push researchers to design studies that explicitly test whether new drugs work equally well in women and men. As the evidence base grows, integrating sex-specific biology into both research design and routine clinical care may be one of the most consequential shifts the field can make for the millions of women living with, or at elevated risk for, this disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
